分化型甲状腺癌术后首次131I治疗前刺激性Tg水平与转移灶的关系

Abstract
Figure/Table
References (13)
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the relationship between first pre-ablation stimulated thyroglobulin(sTg) and sTg/thyrotropin(TSH) levels and metastasis in postoperative patients with differentiated thyroid carcinoma(DTC). Methods: The study included 106 patients with DTC who had undergone total thyroidectomy and lymphadenectomy. The pre-ablation sTg and TSH of 106 patients were measured one day before first 131I ablation therapy, and the patients undergone 131I-SPECT/CT on 5～7 days after 131I ablation therapy. Patients were divided into two groups as M0 group and M1 group according to the presence and absence of metastases, respectively. The sTg and sTg/TSH value between M0 and M1 were compared by Mann-Whitney rank-sun test. The ROC curves and diagnostic critical point(DCP) were analyzed to evaluate the predictive values of sTg and sTg/TSH. Results: The pre-ablation sTg and sTg/TSH of M1 were significantly higher than those of M0(U=242.50, P=0.000; U=237.50, P=0.000). Areas under the ROC curve for sTg and sTg/TSH was 0.913 and 0.914. The cut-off values of DCP of sTg and sTg/TSH were 40.60 ng/mL with a sensitivity of 70.21%, specificity of 100%, accuracy of 86.79%, and 0.24 ng/U with a sensitivity, of 80.85%, specificity of 84.92%, accuracy of 88.68%. Conclusion: The pre-ablation sTg and sTg/TSH may be a useful diagnostic marker for predicting metastases before the first 131I ablation therapy.

Key words： Thyroid neoplasms Tomography, emission-computed, single-photon Iodine

Received: 10 November 2016

PACS:	Ｒ736.1
	Ｒ817.4

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Yong
	CHEN Peng

Cite this article:

LIU Yong,CHEN Peng. The relationship between first pre-ablation sTg levels and metastasis in#br# postoperative patients with differentiated thyroid carcinoma[J]. JOURNAL OF CHINA MEDICAL IMAGING, 2017, 28(7): 471-474.

URL:

http://www.jccmi.com.cn/EN/ OR http://www.jccmi.com.cn/EN/Y2017/V28/I7/471

[1]Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2016, 26(1): 131-133.
[2]林岩松，李娇. 2015年美国甲状腺学会《成人甲状腺结节与分化型甲状腺癌诊治指南》解读：分化型甲状腺癌131I治疗新进展[J]. 中国癌症杂志，2016，26（1）：1-12.
[3]赵腾，梁军，林岩松. 131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义[J]. 国际放射医学核医学杂志，2015，39（1）：61-66.
[4]Kim H, Kim SJ, Kim LJ, et al. Limited clinical value of periablative changes of serum markers in the prediction of biochemical remission in patients with papillary thyroid cancer[J]. Nucl Med Mol Imaging, 2013, 47(4): 268-272.
[5]Ciappuccini R, Hardouin J, Heutte N, et al. Stimulated thyroglobulin level at ablation in differentiated thyroid cancer: the impact of treatment preparation modalities and tumor burden[J]. Eur J Endocrinol, 2014, 171(2): 247-252.
[6]李田军，林岩松，梁军，等. 131I治疗前刺激性Tg对乳头状甲状腺癌远处转移的预测价值[J]. 中华核医学与分子影像杂志，2012，32（3）：189-191.
[7]林岩松，张彬，梁智勇，等. 复发转移性分化型甲状腺癌诊治共识[J]. 中国癌症杂志，2015，25（7）：481-496.
[8]Lim JS, Kim MJ, Yun MJ, et al. Comparison of CT and 18F-FDG PET for detecting peritoneal metastasis on the preoperative evaluation for gastric carcinoma[J]. Kor J Radiol, 2006, 7(4): 249-256.
[9]朱精强. 分化型甲状腺癌颈淋巴结清扫的相关问题[J]. 中国普外基础与临床杂志，2012，19（8）：809.
[10]中华医学会核医学分会. 131I治疗分化型甲状腺癌指南（2014）[J]. 中华核医学与分子影像杂志，2014，34（4）：264-278.
[11]中华医学会内分泌学分会，中华医学会外科学分会内分泌学组，中国抗癌协会头颈肿瘤专业委员会，等. 甲状腺结节和分化型甲状腺癌诊治指南[J]. 中华内分泌代谢杂志，2012，28（10）：779-797.
[12]赵腾，梁军，李田军，等. 分化型甲状腺癌131I治疗前刺激性Tg动态变化与远处转移的关系[J]. 中国医学科学院学报，2015，37（3）：315-319.
[13]Suh I, Vriens MR, Guerrero MA, et al. Serum thyruglobulin is a poor diagnostic biomarker of malignancy in follicular and Hurthle-cell neoplasms of the thyroid[J]. Am J Surg, 2010, 200(1): 41-46.